Diana Ernst, RPh

Editorial Director

Diana Ernst, RPh, is the Editorial Director for MPR, part of the Haymarket Medical Network. Since 2003, Diana has worked to provide healthcare professionals with up-to-date drug information through MPR's print and digital offerings. She is a graduate of the Ernest Mario School of Pharmacy, Rutgers University.

All articles by Diana Ernst, RPh

Infectious Diseases Information Center

Artesunate for Injection Now Available for Severe Malaria

By

Diana Ernst, RPh

April 12, 2021

Artesunate and its metabolite DHA are both active against the blood-stage asexual parasites and gametocytes of Plasmodium species including the chloroquine resistant strains.

Infectious Diseases Information Center

FDA Expands Use of Bioelectronic Device ClearUP to Include Sinus Congestion

By

Diana Ernst, RPh

April 1, 2021

The bioelectronic device was previously approved for treating sinus pain due to allergic rhinitis.

Oncology Information Center

Indications Withdrawn as FDA Evaluates Several Accelerated Approvals

By

Diana Ernst, RPh

March 19, 2021

To prove clinical benefit, the FDA requires manufacturers to conduct confirmatory trials, also known as a phase 4 studies.

Infectious Diseases Information Center

Study Findings Do Not Support Use of Ivermectin for Mild COVID-19

By

Diana Ernst, RPh

March 8, 2021

The median time to resolution of COVID-19 symptoms was 10 days with ivermectin and 12 days with placebo.

Infectious Diseases Information Center

Bamlanivimab Plus Etesevimab Cuts COVID-19 Hospitalizations, Deaths

By

Diana Ernst, RPh

January 28, 2021

The combination therapy reduced the risk of hospitalization or death by 70%.

Practice Management Information Center

Gemtesa Approved for Overactive Bladder Treatment

By

Diana Ernst, RPh

January 21, 2021

The approval was based on data from the pivotal phase 3 EMPOWUR study.

Vaccine Information Center

FDA Urges HCPs to Follow Authorized Dosing Schedules for COVID-19 Vaccines

By

Diana Ernst, RPh

January 14, 2021

Additional research from the vaccine manufacturers would be needed to support any changes to the dosing schedule.

HIV/AIDS Information Center

Counterfeit HIV Drug Identified in 3 US Pharmacies

By

Diana Ernst, RPh

January 4, 2021

The counterfeit products were procured from unauthorized distributors.

Infectious Diseases Information Center

FDA Authorizes COVID-19 Test That Provides Rapid Results at Home

By

Diana Ernst, RPh

November 24, 2020

This is the first time the Agency has authorized a COVID-19 diagnostic test that provides rapid results at home.

Gastroenterology Information Center

FDA Approves Sulfate-Based Tablet Prep for Colonoscopy

By

Diana Ernst, RPh

November 18, 2020

Available as a sulfate-based tablet, Sutab provides an alternative to liquid-based colonoscopy preparations.

Next post in Gastroenterology Information Center

USPSTF Supports Initiating CRC Screening at Age 45 in New Draft Recommendation